SEC Comment Letter 0000000000-25-005063 to Cidara Therapeutics, Inc. (CDTX) (CIK 0001610618)
Cidara Therapeutics, Inc. (CDTX) (CIK 0001610618)
Date: May 13, 2025 · CIK: 0001610618 · Accession: 0000000000-25-005063
AI Filing Summary & Sentiment
File numbers found in text: 333-287104
Letter
May 13, 2025 Jeffrey Stein Chief Executive Officer Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, CA 92121 Re:Cidara Therapeutics, Inc. Registration Statement on Form S-3 Filed May 8, 2025 File No. 333-287104 Dear Jeffrey Stein: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Charles J. Bair, Esq.
Show Raw Text
May 13, 2025
Jeffrey Stein
Chief Executive Officer
Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive, Suite 101
San Diego, CA 92121
Re:Cidara Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 8, 2025
File No. 333-287104
Dear Jeffrey Stein:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Charles J. Bair, Esq.